Parkman Healthcare Partners LLC Decreases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Parkman Healthcare Partners LLC lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,138 shares of the company's stock after selling 14,111 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.09% of Vaxcyte worth $9,507,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PCVX. Wells Fargo & Company MN raised its position in shares of Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after acquiring an additional 25,257 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after buying an additional 4,962 shares during the period. TimesSquare Capital Management LLC increased its position in Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after buying an additional 144,516 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after purchasing an additional 246,049 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $30.05 on Wednesday. The stock's fifty day simple moving average is $44.91 and its 200 day simple moving average is $73.32. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of -6.53 and a beta of 1.27. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the business earned ($0.85) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating for the company. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $136.50.

Insider Activity

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. This represents a 6.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.